LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Product Name RIVAROXABAN FOR ORAL SUSPENSION

Lupin Limited Manufacturer

Chhatrapati Sambhajinagar - 431 210 India

Distributor Lupin Pharmaceuticals, Inc.

> Naples FL, 34108 United States.

Identified uses of the substance or

mixture

Pharmaceutical

Section 2: Hazard(s) Identification

Health May cause damage to organs through prolonged or repeated

exposure. Please refer to the product information insert or product label for appropriate consumer-specific information about this product when used according to the physician's directions.

Environment No Data is available.

Precautionary statements Get medical advice/ attention if you feel unwell.

Section 3: Composition/Information on Ingredients

Ingredients	CAS No.	Ingredients	CAS No.
Rivaroxaban IH	366789-02-8	Sodium benzoate NF	532-32-1
Mannitol USP	69-65-8	Xanthan gum NF	11138-66-2
Citric acid, anhydrous USP	77-92-9	Hydroxypropyl Methyl Cellulose NF	9004-65-3
Sucralose NF	56038-13-2	Purified Water USP	7732-18-5
Microcrystalline cellulose	9004-34-6	Carboxymethyl cellulose sodium USP	9004-32-4

^{*} The exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: First-Aid Measures

General advice Immediate medical attention is required.

Protection of first aiders First Aid responders should pay attention to self-protection and use

the recommended personal protective equipment when the potential

for exposure exists.

Inhaled After inhalation: fresh air. Consult a doctor if the person is feeling

unwell.

SDS: 284/00 Page 1 of 4 Effective Date: 18/08/2025

Skin contact In case of skin contact: Take off immediately all contaminated

clothing. Rinse skin with water/ shower. Consult a physician.

Eve contact After eye contact: rinse out with plenty of water. Remove contact

lenses.

If swallowed After swallowing: immediately make victim drink water (two glasses at

most). Consult a physician. Please refer to the product information

insert.

Section 5: Fire-Fighting Measures

Extinguishing Media Use extinguishing measures that are appropriate to local

circumstances and the surrounding environment.

Special Firefighting Procedures In the event of fire, wear a self-contained breathing apparatus.

Hazardous Combustion Products No information is available.

Section 6: Accidental Release Measures

Personal Precautions In the event of an accidental release the emergency response team

must respond based on a risk assessment and use personal protective

equipment as appropriate. Evacuate personnel to safe areas.

Environmental Precautions It should not be released into the environment.

Clean-up Methods Sweep up into a suitable labeled container for disposal.

Section 7: Handling and Storage

Handling Keep out of the reach of children. Keep away from heat and sources of

ignition. Avoid inhalation, ingestion, contact with skin, and eyes.

Do not freeze.

Store at room temperature between 20°C and 25°C (68°F and 77°F); Storage

excursions permitted between 15°C and 30°C (59°F and 86°F)

Section 8: Exposure Controls/Personal Protection

Engineering Measures/Controls: All personal protective equipment should be based on a risk

assessment. Consult an environmental health Safety expert if

If this product is processed not in accordance with the prescribed use, contact the Industrial Hygiene / Environment Health Safety Expert to

assess the situation.

Personal Protective Equipment: Respiratory: Respiratory protection is generally not needed during

routine conditions.

Eye/Face: When handling very small quantities of the material eye

protection may not be required.

SDS: 284/00

Page 2 of 4 Effective Date: 18/08/2025

Skin/Body: During medical administration of this product, medical latex or nitrile gloves should be worn to avoid absorption of the product.

Section 9: Physical and Chemical Properties

HOW SUPPLIED Rivaroxaban for oral suspension is available in the strengths and

packages listed below:

NDC 70748-355-01 Supplied as white to off-white granules in a translucent HDPE bottle containing 155 mg rivaroxaban, packaged with two oral dosing syringes. After reconstitution with 150 mL of purified water, 1 mL of suspension contains 1 mg rivaroxaban.

Section 10: Stability and Reactivity

Stability The product is chemically stable under standard ambient conditions

(room temperature).

Reactivity None reasonably foreseeable.

Hazardous reactions No dangerous reaction known under conditions of normal use.

Conditions to avoid To avoid thermal decomposition, do not overheat. Heat, flames, and

> sparks. None.

Hazardous decomposition

products

Section 11: Toxicological Information

Acute toxicity

Acute oral toxicity No data available

Acute inhalation toxicity No data available

Acute inhalation toxicity No data available

Inhalation No data available

Skin Contact No data available

Ingestion No data available

Eye Contact No data available

No data available Carcinogenicity

Reproduction toxicity No data available.

Section 12: Ecological Information

SDS: 284/00

Page 3 of 4 Effective Date: 18/08/2025

Ecotoxicity None Identified

Hazardous reactions Product is considered stable.

Conditions to avoidTo avoid thermal decomposition, do not overheat, flames and sparks.

Hazardous decomposition None Known.

products

Section 13: Disposal Considerations

Dispose of contents/containers in accordance with local regulations.

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper Shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated

IMDG Proper Shipping Name:N/AIMDG UN/ID No:N/AIMDG Hazard Class:N/AIMDG Flash Point:N/AIMDG Label:N/A

DOT - Not Regulated

DOT Proper Shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.

Page 4 of 4

SDS: 284/00

Effective Date: 18/08/2025